Posts Tagged ‘natalizumab’

BG-12: The Changing Landscape of Multiple Sclerosis Therapy

Posted by • September 19th, 2012

Multiple sclerosis (MS) remains a leading cause of neurologic disability in the young.  MS usually relapses and remits before entering a progressive phase. We still don’t know the precipitating cause of MS – consequently we have no cure.  Our best approach right now is to try to reduce relapse rate by using drugs that we… Read More…

Natalizumab-Associated PML

Posted by • May 16th, 2012

A new study found that in patients treated with natalizumab, PML incidence was about 11 cases per 1000 patients with 25 to 48 months of treatment, prior immunosuppressant use, and anti–JC virus antibody–positive status. The incidence was estimated to be 0.09 cases or fewer per 1000 antibody-negative patients. Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is approved… Read More…